New chemo injection targets tumors directly in early trial

NCT ID NCT07525141

Recruiting now Disease control Sponsor: Johnson & Johnson Enterprise Innovation Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) helps shrink tumors. About 66 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-1761981 (extended-release chemotherapy) and cetrelimab (immunotherapy)
What this could lead to: If it works, this could offer a new way to treat solid tumors by injecting chemotherapy directly into the tumor, potentially reducing side effects.
What could go wrong: This is an early Phase 1 trial with only 66 participants, focused on safety and dosing. It may not lead to an effective treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.